|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US3931155A
(en)
|
1973-04-25 |
1976-01-06 |
Richardson-Merrell Inc. |
Process for preparing 2-azacycloalkylmethyl ketones
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
AU598946B2
(en)
|
1987-06-24 |
1990-07-05 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5859221A
(en)
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
BR9106702A
(pt)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals Inc |
Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
US5948903A
(en)
|
1991-01-11 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Synthesis of 3-deazapurines
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
AU3222793A
(en)
|
1991-11-26 |
1993-06-28 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
AU9063398A
(en)
|
1997-09-12 |
1999-04-05 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
EP1178999B1
(en)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analogues
|
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
|
US20030175906A1
(en)
|
2001-07-03 |
2003-09-18 |
Muthiah Manoharan |
Nuclease resistant chimeric oligonucleotides
|
|
US20030158403A1
(en)
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
|
EP1661905B9
(en)
|
2003-08-28 |
2012-12-19 |
IMANISHI, Takeshi |
Novel artificial nucleic acids of n-o bond crosslinkage type
|
|
WO2005027962A1
(en)
|
2003-09-18 |
2005-03-31 |
Isis Pharmaceuticals, Inc. |
4’-thionucleosides and oligomeric compounds
|
|
WO2005041899A2
(en)
|
2003-11-03 |
2005-05-12 |
University Of Virginia Patent Foundation |
Orally available sphingosine 1-phosphate receptor agonists and antagonists
|
|
WO2005056577A2
(en)
|
2003-12-05 |
2005-06-23 |
The Regents Of The University Of California |
Peptide inhibitors of hiv
|
|
US20070258970A1
(en)
|
2003-12-09 |
2007-11-08 |
Robert Blumenthal |
Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
|
|
WO2005122379A2
(en)
|
2004-05-27 |
2005-12-22 |
The Regents Of The University Of California |
Alpha-4 beta-1 integrin ligands for imaging and therapy
|
|
MX2007001661A
(es)
|
2004-08-13 |
2007-04-23 |
Praecis Pharm Inc |
Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
|
|
CA2627502C
(en)
|
2005-10-31 |
2014-04-01 |
Toray Fine Chemicals Co., Ltd. |
Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
６−修飾された二環式核酸類似体
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
ES2414205T3
(es)
|
2006-06-02 |
2013-07-18 |
The Ohio State University Research Foundation |
Agentes terapéuticos para el tratamiento de linfoma de células del manto
|
|
CN101460456A
(zh)
|
2006-06-06 |
2009-06-17 |
国立大学法人岐阜大学 |
抑制神经源性疼痛的吡咯烷类似物及其制造方法
|
|
US20080070866A1
(en)
|
2006-08-01 |
2008-03-20 |
Praecis Pharmaceuticals Incorporated |
Chemical compounds
|
|
EP2066630A1
(en)
|
2006-08-23 |
2009-06-10 |
Pfizer Products Incorporated |
Piperidine derivatives
|
|
CL2007003784A1
(es)
|
2006-12-21 |
2008-06-27 |
Abbott Lab |
Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato
|
|
WO2008097819A2
(en)
|
2007-02-05 |
2008-08-14 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US20100190837A1
(en)
|
2007-02-15 |
2010-07-29 |
Isis Pharmaceuticals, Inc. |
5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
|
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
EP2173760B2
(en)
|
2007-06-08 |
2015-11-04 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
CA2692579C
(en)
|
2007-07-05 |
2016-05-03 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
WO2009023855A2
(en)
|
2007-08-15 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
|
WO2009053481A1
(en)
*
|
2007-10-25 |
2009-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Compositions and methods for modulating nk and t cell trafficking
|
|
US8546556B2
(en)
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
|
WO2009100320A2
(en)
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
WO2009106599A2
(en)
|
2008-02-29 |
2009-09-03 |
Novartis Ag |
Substituted piperidines as therapeutic compounds
|
|
GB0811451D0
(en)
|
2008-06-20 |
2008-07-30 |
Syngenta Participations Ag |
Novel microbiocides
|
|
WO2010009762A1
(en)
|
2008-07-23 |
2010-01-28 |
United Technologies Ut Ag |
Interferon and an agent inducing inhibition of protein phosphatase 2a such as interleukin- 1 and optionally ribavirin for the treatment of hbv or hcv infection
|
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
US20110086869A1
(en)
|
2009-09-24 |
2011-04-14 |
The Trustees Of Boston University |
Methods for treating viral disorders
|
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
|
US8309768B2
(en)
*
|
2010-11-29 |
2012-11-13 |
The Ohio State University Research Foundation |
FTY720-derived anticancer agents
|
|
FR2968556B1
(fr)
|
2010-12-13 |
2013-12-27 |
Centre Nat Rech Scient |
Inhibiteurs des infections a vih et leurs utilisations
|
|
WO2014118556A2
(en)
|
2013-01-31 |
2014-08-07 |
Research Foundation Of The City University Of New York |
Selective inhibitors and allosteric activators of sphingosine kinase
|
|
TWI613182B
(zh)
*
|
2013-02-21 |
2018-02-01 |
必治妥美雅史谷比公司 |
雙環化合物
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
EP3022176B8
(en)
|
2013-07-15 |
2019-12-25 |
The Regents of the University of California |
Azacyclic constrained analogs of fty720
|
|
WO2015106128A2
(en)
|
2014-01-09 |
2015-07-16 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED RNAi AGENTS
|
|
WO2016160102A1
(en)
|
2015-03-31 |
2016-10-06 |
Lam Therapeutics, Inc. |
Active metabolites of apilimod and uses thereof
|
|
CN108779073A
(zh)
|
2015-06-23 |
2018-11-09 |
凯斯西储大学 |
用于治疗癌症的组合物和方法
|
|
EP3352753A4
(en)
|
2015-09-24 |
2019-03-13 |
The Regents of The University of California |
SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
|
|
JP2022500352A
(ja)
|
2018-06-14 |
2022-01-04 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
合成細胞毒性分子、薬剤、それらの合成法および処置法
|
|
WO2021062168A1
(en)
|
2019-09-25 |
2021-04-01 |
The Regents Of The University Of California |
Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
|
|
CA3158256A1
(en)
|
2019-11-13 |
2021-05-20 |
Aimee EDINGER |
Drug formulations and methods of treatment for metabolic disorders
|
|
EP4149625A4
(en)
|
2020-05-16 |
2024-06-12 |
Viratides, LLC |
TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTIONS WITH LIPID AGENTS
|
|
WO2022094615A1
(en)
|
2020-10-29 |
2022-05-05 |
The Regents Of The University Of California |
Compounds and methods for increased antisense activity
|
|
WO2022133494A1
(en)
|
2020-12-17 |
2022-06-23 |
The Regents Of The University Of California |
Antiviral compounds and applications thereof
|